A public-private council report outlining industry views on Japan’s drug pricing systems drew little discussion at a meeting of the…
BUSINESS
Astellas Looks at Iveric Bio’s Eye Drug as 3rd Biz Pillar to Counter Xtandi Cliff
Astellas Pharma is set to capitalize on an eye drug to be acquired through the buyout of Iveric Bio as a “third pillar” of its business that will make up for an anticipated patent cliff of its blockbuster cancer med…
To read the full story
Related Article
- Iveric Bio’s AMD Drug Approved in US, Launch Set for This Month: Astellas
August 8, 2023
- Astellas’ Iveric Bio Acquisition Completed
July 13, 2023
- Astellas to Snap Up Iveric Bio for US$5.9 Billion
May 1, 2023
BUSINESS
- Nipro, Nichi-Iko to Consolidate Injectable Antibiotics Production by 2026
November 7, 2025
- Teijin Debuts Yorvipath in Japan, Eyes Rare Disease Growth
November 7, 2025
- Genmab Seeks Label Expansion for Epkinly Combo Use in Japan
November 7, 2025
- Alfresa, K Pharma Tie Up on iPS Cell-Derived Therapy KP8011
November 7, 2025
- Fujifilm to Launch ADC-Focused CDMO Services First in Japan
November 7, 2025
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
In the complex tapestry of leadership, awareness isn’t just a desirable trait; it’s the bedrock upon which success is built. It’s the lens through which leaders perceive, interpret, and navigate the ever-shifting landscape of their organizations and industries. Without it,…
Japan’s drug wholesalers are facing mounting financial pressure as rising logistics and procurement costs deepen losses on product distribution, even…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…